Phaseline

Targets › IMPDH2

IMPDH2 (Inosine-5'-monophosphate dehydrogenase 2): drug programs, companies and trials

4 programs from 4 companies in 23 trials: 9 Phase 4, 7 Phase 2, 5 Phase 1, 2 Phase 3; Genitourinary, Oncology, Hematology; next expected readout Nov 2026.

Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. (UniProt, P12268)

Open in Phaseline: the race on IMPDH2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chong Kun Dang PharmaceuticalMycophenolate Mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 4Kidney Transplantation; Hypersensitivity Pneumonitis; Liver Transplantation; Lupus Nephritis …Nov 2026
University of California, DavisReduction in antimetabolite immunosuppression
Transient reduction in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine dosin
IMPDH2Phase 4COVID-19Dec 2026
Mats HeymanThioguanine
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 3Leukemia, Acute LymphoblasticJun 2033
RocheMycophenolate Mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 3Childhood Idiopathic Nephrotic Syndrome–

Conditions

Kidney Transplantation (4) Lupus Nephritis (2) Hypersensitivity Pneumonitis (1) Liver Transplantation (1) IgA Nephropathy (1) Systemic Sclerosis With Lung Involvement (1) Acute Myelogenous Leukemia (1) Immune-mediated Hepatitis (1) Lymphoma, Non-Hodgkin (1) Hematological Malignancies (1) Immunodeficiency (1) Graft Versus Host Disease (1)

Modalities

small molecule (2), mixed (2)

Companies

Chong Kun Dang Pharmaceutical (1) University of California, Davis (1) Mats Heyman (1) Roche (1)

Related targets

IMPDH1 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.